Comparative Study
doi: 10.1007/BF01964274.
In vitro susceptibility of Helicobacter pylori to the new oral cephalosporins cefpodoxime, ceftibuten and cefixime
Affiliations
- PMID: 2226500
- DOI: 10.1007/BF01964274
Item in Clipboard
Comparative Study
In vitro susceptibility of Helicobacter pylori to the new oral cephalosporins cefpodoxime, ceftibuten and cefixime
Eur J Clin Microbiol Infect Dis.
1990 Sep.
Abstract
The in vitro activity against 30 Helicobacter pylori strains of three new third generation cephalosporins, cefpodoxime, ceftibuten and cefixime, which can be administered orally, was determined using an agar dilution technique under microaerophilic conditions. The MIC50 and MIC90 of cefpodoxime was 0.5 and 4.0 micrograms/ml respectively, of ceftibuten 2.0 and 8.0 micrograms/ml, and of cefixime 0.06 and 0.5 microgram/ml. All antibiotics showed good activity against Helicobacter pylori, cefixime having the highest activity of the three agents.
Similar articles
-
Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil.Infection. 1991 Sep-Oct;19(5):353-62. doi: 10.1007/BF01645369. Infection. 1991. PMID: 1800377
-
Comparative antimicrobial spectrum and activity of ceftibuten against clinical isolates from West Germany.Diagn Microbiol Infect Dis. 1991 Jan-Feb;14(1):63-74. doi: 10.1016/0732-8893(91)90091-s. Diagn Microbiol Infect Dis. 1991. PMID: 2013211
-
In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers.Diagn Microbiol Infect Dis. 1993 Aug-Sep;17(2):143-50. doi: 10.1016/0732-8893(93)90025-3. Diagn Microbiol Infect Dis. 1993. PMID: 8243035
-
Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten.Ann Pharmacother. 1996 Mar;30(3):258-68. doi: 10.1177/106002809603000310. Ann Pharmacother. 1996. PMID: 8833562 Review.
-
Antimicrobial activity and spectrum of ceftibuten (7432-S, SCH 39720)--a review of United States and Canadian results.Diagn Microbiol Infect Dis. 1991 Jan-Feb;14(1):37-43. doi: 10.1016/0732-8893(91)90088-w. Diagn Microbiol Infect Dis. 1991. PMID: 2013209 Review.
Cited by
-
Helicobacter pylori infection in a pediatric population: in vitro susceptibilities to omeprazole and eight antimicrobial agents.Antimicrob Agents Chemother. 1992 May;36(5):1133-5. doi: 10.1128/AAC.36.5.1133. Antimicrob Agents Chemother. 1992. PMID: 1510406 Free PMC article.
-
Ceftibuten pharmacokinetics and pharmacodynamics. Focus on paediatric use.Clin Pharmacokinet. 1994 Mar;26(3):169-89. doi: 10.2165/00003088-199426030-00002. Clin Pharmacokinet. 1994. PMID: 8194281 Review.
-
A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.Drug Saf. 1996 Jul;15(1):30-52. doi: 10.2165/00002018-199615010-00003. Drug Saf. 1996. PMID: 8862962 Review.
-
In vitro susceptibility of Helicobacter pylori to trospectomycin, pirlimycin (U-57930E), mirincamycin (U-24729A) and N-demethyl clindamycin (U-26767A).Eur J Clin Microbiol Infect Dis. 1993 Jul;12(7):560-2. doi: 10.1007/BF01970966. Eur J Clin Microbiol Infect Dis. 1993. PMID: 8404921
-
Antibacterial properties of lansoprazole alone and in combination with antimicrobial agents against Helicobacter pylori.Eur J Clin Microbiol Infect Dis. 1995 May;14(5):391-9. doi: 10.1007/BF02114894. Eur J Clin Microbiol Infect Dis. 1995. PMID: 7556227